Literature DB >> 35218135

Prioritizing prevention of de novo and worsening chronic heart failure.

Ankeet S Bhatt1, Gregg C Fonarow2, Stephen J Greene3,4.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35218135      PMCID： PMC9106859          DOI： 10.1002/ejhf.2464

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   17.349


× No keyword cloud information.
  20 in total

1.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  J Am Coll Cardiol       Date:  2018-11-10       Impact factor: 24.094

2.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

3.  Contextualizing Risk Among Patients With Heart Failure.

Authors:  Stephen J Greene; Javed Butler; Gregg C Fonarow
Journal:  JAMA       Date:  2021-12-14       Impact factor: 56.272

4.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Hugo J Aparicio; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Susan Cheng; Francesca N Delling; Mitchell S V Elkind; Kelly R Evenson; Jane F Ferguson; Deepak K Gupta; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Chong D Lee; Tené T Lewis; Junxiu Liu; Matthew Shane Loop; Pamela L Lutsey; Jun Ma; Jason Mackey; Seth S Martin; David B Matchar; Michael E Mussolino; Sankar D Navaneethan; Amanda Marma Perak; Gregory A Roth; Zainab Samad; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Andrew Stokes; Lisa B VanWagner; Nae-Yuh Wang; Connie W Tsao
Journal:  Circulation       Date:  2021-01-27       Impact factor: 29.690

5.  In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

Authors:  Kiran Musunuru; Alexandra C Chadwick; Taiji Mizoguchi; Sara P Garcia; Jamie E DeNizio; Caroline W Reiss; Kui Wang; Sowmya Iyer; Chaitali Dutta; Victoria Clendaniel; Michael Amaonye; Aaron Beach; Kathleen Berth; Souvik Biswas; Maurine C Braun; Huei-Mei Chen; Thomas V Colace; John D Ganey; Soumyashree A Gangopadhyay; Ryan Garrity; Lisa N Kasiewicz; Jennifer Lavoie; James A Madsen; Yuri Matsumoto; Anne Marie Mazzola; Yusuf S Nasrullah; Joseph Nneji; Huilan Ren; Athul Sanjeev; Madeleine Shay; Mary R Stahley; Steven H Y Fan; Ying K Tam; Nicole M Gaudelli; Giuseppe Ciaramella; Leslie E Stolz; Padma Malyala; Christopher J Cheng; Kallanthottathil G Rajeev; Ellen Rohde; Andrew M Bellinger; Sekar Kathiresan
Journal:  Nature       Date:  2021-05-19       Impact factor: 69.504

6.  Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry.

Authors:  Jasper Tromp; Joost C Beusekamp; Wouter Ouwerkerk; Peter van der Meer; John G F Cleland; Christiane E Angermann; Ulf Dahlstrom; Georg Ertl; Mahmoud Hassanein; Sergio V Perrone; Mathieu Ghadanfar; Anja Schweizer; Achim Obergfell; Gerasimos Filippatos; Kenneth Dickstein; Sean P Collins; Carolyn S P Lam
Journal:  Eur J Heart Fail       Date:  2022-02-17       Impact factor: 17.349

7.  Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study.

Authors:  Clare J Taylor; José M Ordóñez-Mena; Andrea K Roalfe; Sarah Lay-Flurrie; Nicholas R Jones; Tom Marshall; F D Richard Hobbs
Journal:  BMJ       Date:  2019-02-13

8.  Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Authors:  Alice M Jackson; Pardeep S Jhund; Inder S Anand; Hans-Dirk Düngen; Carolyn S P Lam; Marty P Lefkowitz; Gerard Linssen; Lars H Lund; Aldo P Maggioni; Marc A Pfeffer; Jean L Rouleau; Jose F K Saraiva; Michele Senni; Orly Vardeny; Magnus O Wijkman; Mehmet B Yilmaz; Yoshihiko Saito; Michael R Zile; Scott D Solomon; John J V McMurray
Journal:  Eur Heart J       Date:  2021-09-21       Impact factor: 29.983

9.  Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Authors:  Milton Packer; Javed Butler; Faiez Zannad; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Sven Schnaidt; Cordula Zeller; Janet M Schnee; Stefan D Anker
Journal:  Circulation       Date:  2021-08-29       Impact factor: 29.690

10.  Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.

Authors:  Faiez Zannad; João Pedro Ferreira; Stuart J Pocock; Cordula Zeller; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Sibylle Jenny Hauske; Martina Brueckmann; Egon Pfarr; Janet Schnee; Christoph Wanner; Milton Packer
Journal:  Circulation       Date:  2020-10-23       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.